SCHEMBL3039984

SCHEMBL3039984

O=C(O)c1ccc(S(=O)(=O)N(Oc2ccc(Br)cc2)c2cccc(F)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 13/20 0.47
NR4A2 P43354 1/20 0.42
PTGES O14684 4/20 0.41
ALOX5 P09917 1/20 0.41
IDO1 P14902 1/20 0.40
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
TAS2R8 Q9NYW2 1/20 0.38
CXCR3 P49682 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3049479 0.92 TAS2R14 (0.50) TAS2R14NR4A2PTGESALOX5ALDH1A1
SCHEMBL3050568 0.91 TAS2R14 (0.54) TAS2R14NR4A2PTGESALOX5ALDH1A1
SCHEMBL3054754 0.87 PTGES (0.47) TAS2R14PTGESALOX5IDO1ALDH1A1
SCHEMBL3054532 0.86 USP5 (0.45) TAS2R14IDO1ALDH1A1KMT2A
SCHEMBL3050794 0.82 TAS2R14 (0.54) TAS2R14PTGESALOX5ALDH1A1KMT2A
SCHEMBL3052354 0.80 SMN1; SMN2 (0.44) ALDH1A1KMT2A
SCHEMBL3274446 0.78 USP5 (0.47) TAS2R14IDO1ALDH1A1
SCHEMBL2897962 0.78 PTGES (0.52) TAS2R14PTGESALOX5ALDH1A1KMT2A
SCHEMBL15016253 0.75 ITGB3 (0.38) ALDH1A1
SCHEMBL3046480 0.75 CXCR3 (0.38) CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP disclosed
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2013-01-31 US disclosed
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2012-11-22 US disclosed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed
EP-2074083-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-01 EP disclosed
EP-2057116-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-05-13 EP disclosed
WO-2008050167-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed
WO-2008050168-A1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 TAS2R14 211/4885NR4A2 2129/4885PTGES 618/4885
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 TAS2R14 463/4885NR4A2 2437/4885PTGES 359/4885
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 TAS2R14 243/4885NR4A2 2174/4885PTGES 540/4885
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 TAS2R14 287/4885NR4A2 2264/4885PTGES 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.